Cargando…
Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent
The degree of tumor removal at surgery is a major factor in predicting outcome for ovarian cancer. A single multimodality agent that can be used with magnetic resonance (MR) for staging and pre-surgical planning, and with optical imaging to aid surgical removal of tumors, would present a new paradig...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177955/ https://www.ncbi.nlm.nih.gov/pubmed/28004770 http://dx.doi.org/10.1038/srep38991 |
_version_ | 1782485088422854656 |
---|---|
author | Ravoori, M. K. Singh, S. Bhavane, R. Sood, A. K. Anvari, B. Bankson, J. Annapragada, A. Kundra, V. |
author_facet | Ravoori, M. K. Singh, S. Bhavane, R. Sood, A. K. Anvari, B. Bankson, J. Annapragada, A. Kundra, V. |
author_sort | Ravoori, M. K. |
collection | PubMed |
description | The degree of tumor removal at surgery is a major factor in predicting outcome for ovarian cancer. A single multimodality agent that can be used with magnetic resonance (MR) for staging and pre-surgical planning, and with optical imaging to aid surgical removal of tumors, would present a new paradigm for ovarian cancer. We assessed whether a dual-mode, dual-Gadolinium (DM-Dual-Gd-ICG) contrast agent can be used to visualize ovarian tumors in the peritoneal cavity by multimodal MR and near infra-red imaging (NIR). Intraperitoneal ovarian tumors (Hey-A8 or OVCAR3) in mice enhanced on MR two days after intravenous DM-Dual Gd-ICG injection compared to controls (SNR, CNR, p < 0.05, n = 6). As seen on open abdomen and excised tumors views and confirmed by optical radiant efficiency measurement, Hey-A8 or OVCAR3 tumors from animals injected with DM-Dual Gd-ICG had increased fluorescence (p < 0.05, n = 6). This suggests clinical potential to localize ovarian tumors by MR for staging and surgical planning, and, by NIR at surgery for resection. |
format | Online Article Text |
id | pubmed-5177955 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-51779552016-12-29 Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent Ravoori, M. K. Singh, S. Bhavane, R. Sood, A. K. Anvari, B. Bankson, J. Annapragada, A. Kundra, V. Sci Rep Article The degree of tumor removal at surgery is a major factor in predicting outcome for ovarian cancer. A single multimodality agent that can be used with magnetic resonance (MR) for staging and pre-surgical planning, and with optical imaging to aid surgical removal of tumors, would present a new paradigm for ovarian cancer. We assessed whether a dual-mode, dual-Gadolinium (DM-Dual-Gd-ICG) contrast agent can be used to visualize ovarian tumors in the peritoneal cavity by multimodal MR and near infra-red imaging (NIR). Intraperitoneal ovarian tumors (Hey-A8 or OVCAR3) in mice enhanced on MR two days after intravenous DM-Dual Gd-ICG injection compared to controls (SNR, CNR, p < 0.05, n = 6). As seen on open abdomen and excised tumors views and confirmed by optical radiant efficiency measurement, Hey-A8 or OVCAR3 tumors from animals injected with DM-Dual Gd-ICG had increased fluorescence (p < 0.05, n = 6). This suggests clinical potential to localize ovarian tumors by MR for staging and surgical planning, and, by NIR at surgery for resection. Nature Publishing Group 2016-12-22 /pmc/articles/PMC5177955/ /pubmed/28004770 http://dx.doi.org/10.1038/srep38991 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Ravoori, M. K. Singh, S. Bhavane, R. Sood, A. K. Anvari, B. Bankson, J. Annapragada, A. Kundra, V. Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent |
title | Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent |
title_full | Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent |
title_fullStr | Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent |
title_full_unstemmed | Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent |
title_short | Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent |
title_sort | multimodal magnetic resonance and near-infrared-fluorescent imaging of intraperitoneal ovarian cancer using a dual-mode-dual-gadolinium liposomal contrast agent |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177955/ https://www.ncbi.nlm.nih.gov/pubmed/28004770 http://dx.doi.org/10.1038/srep38991 |
work_keys_str_mv | AT ravoorimk multimodalmagneticresonanceandnearinfraredfluorescentimagingofintraperitonealovariancancerusingadualmodedualgadoliniumliposomalcontrastagent AT singhs multimodalmagneticresonanceandnearinfraredfluorescentimagingofintraperitonealovariancancerusingadualmodedualgadoliniumliposomalcontrastagent AT bhavaner multimodalmagneticresonanceandnearinfraredfluorescentimagingofintraperitonealovariancancerusingadualmodedualgadoliniumliposomalcontrastagent AT soodak multimodalmagneticresonanceandnearinfraredfluorescentimagingofintraperitonealovariancancerusingadualmodedualgadoliniumliposomalcontrastagent AT anvarib multimodalmagneticresonanceandnearinfraredfluorescentimagingofintraperitonealovariancancerusingadualmodedualgadoliniumliposomalcontrastagent AT banksonj multimodalmagneticresonanceandnearinfraredfluorescentimagingofintraperitonealovariancancerusingadualmodedualgadoliniumliposomalcontrastagent AT annapragadaa multimodalmagneticresonanceandnearinfraredfluorescentimagingofintraperitonealovariancancerusingadualmodedualgadoliniumliposomalcontrastagent AT kundrav multimodalmagneticresonanceandnearinfraredfluorescentimagingofintraperitonealovariancancerusingadualmodedualgadoliniumliposomalcontrastagent |